ARS Pharmaceuticals 株価情報 (NASDAQ: SPRY)

最新ニュース ARS Pharmaceuticals (NASDAQ:SPRY) 株価情報

ARS Pharmaceuticals

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

ARS Pharmaceuticals Inc

Barclays analyst Lydia Rainforth upgrades Equinor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Equal-Weight to Overweight.

News

Upgrades

Analyst Ratings

EQNR

Barclays Upgrades Equinor to Overweight

EnLink Midstream, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) shares traded higher premarket on Monday after it disclosed a merger deal with ONEOK, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) for $4.3 billion.
As per the deal, each EnLink common unit not owned by ONEOK will be exchanged for <a target="_blank" href="https://www.benzinga.com//node/42155913" rel="noreferrer noopener">0.1412 shares of ONEOK stock.</a>
This exchange ratio reflects EnLink&#8217;s closing price of $15.75 on November 22, 2024, divided by ONEOK&#8217;s 10-day volume-weighted average price (VWAP).
ONEOK will issue approximately 37 million shares, representing about 6% of its total shares outstanding after the transaction.
ONEOK, which holds approximately 44% of EnLink&#8217;s common units, has committed to voting in favor of the transaction.
The transaction, subject to customary closing conditions, is expected to close in the first quarter of 2025.
The merger&#8217;s completion requires approval from a majority of EnLink&#8217;s outstanding common units, including those owned by ONEOK, and satisfaction of other customary closing conditions.
Pierce H. Norton II, ONEOK president and chief executive officer, said, &#8220;This tax-free transaction to acquire the remaining outstanding EnLink units is expected to be accretive to ONEOK shareholders and provide EnLink unitholders with significantly greater trading liquidity and an attractive dividend yield.&#8221;&nbsp;&nbsp;
In October 15, 2024, ONEOK disclosed the successful completion of its acquisition of Global Infrastructure Partners&#8217; (GIP) entire interest in EnLink for a total cash <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40626128/oneok-spends-3b-on-enlink-midstream-stake-2-6b-on-medallion" rel="noreferrer noopener">consideration of approximately&nbsp;$3.3 billion</a>.
Investors can gain exposure to the OKE stock via&nbsp;Global X MLP &amp; Energy Infrastructure ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLPX#NYSE">MLPX</a>) and Tortoise North American Pipeline ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPYP#NYSE">TPYP</a>).
Price Action: ENLC shares are up 1.27% at $15.95 premarket at the last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42118286/7-us-natural-gas-stocks-to-watch-as-henry-hub-prices-surge-50-in-november" target="_blank" rel="noreferrer noopener">7 US Natural Gas Stocks To Watch As Henry Hub Prices Surge 50% In November</a></li>
</ul>

Equities

Mid Cap

ENLC

MLPX

TPYP

ONEOK Bolsters Portfolio With EnLink Acquisition, $4.3 Billion Deal Unveiled

Wedbush analyst Daniel Ives maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Outperform and raises the price target from $325 to $375.

Price Target

Wedbush Maintains Outperform on Salesforce, Raises Price Target to $375

UHAL

U-Haul Expands Kingsport Operations With Acquisition Of All Season Storage On Fort Henry Drive

JP Morgan analyst Domingos Falavina upgrades Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSBR#NYSE">BSBR</a>) from Neutral to Overweight and lowers the price target from $7 to $6.

BSBR

JP Morgan Upgrades Banco Santander to Overweight, Lowers Price Target to $6

JP Morgan analyst Domingos Falavina downgrades Bank Bradesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBD#NYSE">BBD</a>) from Overweight to Neutral.

Downgrades

JP Morgan Downgrades Bank Bradesco to Neutral

Wedbush analyst Daniel Ives maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Outperform and raises the price target from $57 to $75.

PLTR

Wedbush Maintains Outperform on Palantir Technologies, Raises Price Target to $75

JP Morgan analyst Jeffrey Zekauskas reinstates Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Overweight and announces $76 price target.

Initiation

BERY

JP Morgan Reinstates Overweight on Berry Global Gr, Announces $76 Price Target

On Friday, November 22, U.S. markets closed higher, with all major indexes recording weekly gains. Optimism was driven by robust U.S. business activity and expectations of interest rate cuts.
However, tech faced pressure as Alphabet fell amid antitrust scrutiny, and Nvidia slipped following a cautious forecast. Investors also weighed geopolitical tensions, including Ukraine-Russia conflicts, and anticipated key developments, such as Trump&#8217;s Treasury Secretary selection.
According to economic data, the S&amp;P Global U.S. Services PMI rose to 57 in November from 55, while Manufacturing PMI edged up to 48.8 from 48.5. However, U.S. consumer sentiment dropped to 71.8, down from a preliminary 73 reading.
Industrials, financials, and consumer discretionary stocks led S&amp;P 500 gains Friday, while utilities and communication services lagged.
The Dow Jones Industrial Average was up 0.97% and closed at 44,296.51, the S&amp;P 500 gained 0.35% to 5,969.30, and the Nasdaq Composite rose 0.16% to finish at 19,003.65.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 gained 1.08% and ended the session at 38,735.00, led by gains in the Chemical, Petroleum &amp; Plastic, Mining and Textile sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.28% and ended the day at 8,417.60, led by gains in the A-REITs, Healthcare, and Consumer Discretionary sectors.</li>
<li>India&#8217;s Nifty 50 rose 1.32% to 24,221.90, and Nifty 500 gained 1.58%, closing at 22,576.60, led by gains in the Oil &amp; Gas, Capital Goods, and Public Sector Undertakings sectors.</li>
<li>China&#8217;s Shanghai Composite declined 0.10% to close at 3,263.76, and the Shenzhen CSI 300 fell 0.46%, finishing the day at 3,848.09.</li>
<li>Hong Kong&#8217;s Hang Seng fell 0.41% and closed the session at 19,150.99.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 index was up 0.35%.</li>
<li>Germany&#8217;s DAX rose 0.45%.</li>
<li>France&#8217;s CAC gained 0.12%.</li>
<li>U.K.&#8217;s FTSE 100 index traded higher by 0.12%</li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.42% at $70.94/bbl, and Brent was down 0.40% at $74.32/bbl.</li>
<li>Oil prices steadied after last week&#8217;s 6% gains, driven by geopolitical tensions involving Russia and Iran. Markets await the OPEC+ meeting and rising Chinese crude demand, while potential U.S. sanctions on Iran threaten supply disruptions.</li>
<li>Natural Gas rose 3.99% to $3.418.</li>
<li>Gold was trading lower by 1.21% at $2,703.90, Silver was down 1.56% to $31.282, and Copper gained 0.67% to $4.1612.</li>
</ul>
U.S. Futures at 06:00 AM ET
Dow futures gained 0.68%, S&amp;P 500 futures were up 0.51% and Nasdaq 100 futures rose 0.61%.
Forex at 06:00 AM ET
The U.S. dollar index fell 0.55% to 106.97, the USD/JPY was down 0.23% to 154.38, and the USD/AUD rose 0.39% to 1.5355.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mixed, Europe Markets Gain While Gold And Dollar Dip - Global Markets Today While US Slept

<ul>
<li>The transaction will be implemented pursuant to a previously announced prearranged chapter 11 plan supported and funded by 100 percent of CareMax's current secured lenders (the "Prearranged Plan"). The sale of the Core Centers' Assets is anticipated to be consummated simultaneously with CareMax's Prearranged Plan.</li>
<li>CareMax has obtained Court approval to maintain business-as-usual operations to ensure the Company's medical centers and physician affiliates continue providing uninterrupted, high-quality care and service to all patients.</li>
</ul>

Health Care

General

CMAX

ClareMedica Health Partners Has Entered Into A "Stalking Horse" Purchase Agreement With CareMax To Purchase CareMax's Core Centers' Assets Including A Vast Majority Of CareMax's Operating Clinics

Under the terms of the agreement BXCI will provide EQT $3.5 billion of cash consideration in exchange for a non-controlling common equity interest in the JV.&nbsp;
The investment implies a total JV valuation of approximately $8.8 billion, or 12x EBITDA. The JV provides EQT with a large-scale equity capital solution at an accretive cost of capital.&nbsp;
Additionally, EQT will retain the rights to growth projects associated with the assets contributed to the JV, including the planned Mountain Valley Pipeline ("MVP") expansion and the MVP Southgate project.
EQT plans to use proceeds from this transaction to pay down its term loan and revolving credit facility and redeem and tender for senior notes.&nbsp;
 &nbsp;

EQT Enters Definitive Agreement With Funds Managed By Blackstone Credit & Insurance To Form New $3.5B Midstream Joint Venture

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.gctsemi.com&amp;esheet=54157480&amp;newsitemid=20241125186361&amp;lan=en-US&amp;anchor=GCT+Semiconductor+Holding+Inc.&amp;index=1&amp;md5=b1d413e4a77dc13f33b9a00307a04cc3">GCT Semiconductor Holding Inc.</a> ("GCT" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>), a leading designer and supplier of advanced 5G and 4G semiconductor solutions, announced today the signing of a definitive agreement with a European tier one wireless infrastructure and terminal provider (the "Tier One Supplier") to collaborate on the development of Fixed Wireless Access ("FWA") technology using GCT's 5G solutions including modem chipset and RFIC.
The Company previously announced the signing of an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pressviewer.com%2Fprofiles%2Finvestor%2FNewsPrint.asp%3Fv%3D6%26b%3D2932%26ID%3D137001%26m%3Drl%26g%3D2763&amp;esheet=54157480&amp;newsitemid=20241125186361&amp;lan=en-US&amp;anchor=MOU+with+the+Tier+One+Supplier&amp;index=2&amp;md5=22076aa6120c7cd56d052f4fe151f7b7">MOU with the Tier One Supplier</a> in August 2024, a continuation of an existing key customer relationship now moving to 5G. GCT expects the launch of FWA devices related to this activity to commence in the second half of 2025.
"This collaboration is a major milestone and reinforces the momentum we are gaining in solidifying customer engagement and strengthening client relationships for growth as we prepare for our 5G chipset launch," said John Schlaefer, CEO of GCT. "We look forward to working together on this significant partner's 5G portfolio and high-performing FWA technology."
The growing 5G FWA technology is a cost-effective alternative to traditional wired broadband options and offers reliable connectivity in remote or underserved areas. Based on the Ericsson Mobility Report (June 2024)&#x2A;, the number of 5G FWA connections worldwide is projected to increase over 800% from the end of 2023 to the end of 2029, representing an increase from ~30 million connections to ~280 million connections. With its strong expertise in 5G chip development, GCT is fully prepared to take advantage of this growing market.

GCTS

GCT Semiconductor Teams Up with European Supplier to Drive 5G Fixed Wireless Access Innovation, Targets 2025 Device Launch

Nasdaq will file a delisting notice with the SEC. Oncternal has stated it will not appeal the decision.
&nbsp;

Biotech

ONCT

On November 22, Oncternal Therapeutics Announced That Nasdaq Plans To Delist Its Stock On December 3, Nasdaq Classified The Company As "Public Shell,"  Following Its Decision To Lay Off Employees And Explore Strategic Alternatives-Filing

Wedbush analyst Daniel Ives upgrades Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from Neutral to Outperform and announces $135 price target.

ESTC

Wedbush Upgrades Elastic to Outperform, Announces $135 Price Target

JP Morgan analyst Michael Rehaut downgrades Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) from Overweight to Neutral and lowers the price target from $41 to $36.

SDHC

JP Morgan Downgrades Smith Douglas Homes to Neutral, Lowers Price Target to $36

Elon Musk&#8217;s Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is actively recruiting software engineers to enhance its teleoperation <a href="https://www.benzinga.com/topic/tesla-cybercab">capabilities for robotaxis</a> and <a href="https://www.benzinga.com/topic/tesla-optimus">the Optimus robot</a>.
What Happened: The initiative, spearheaded by Tesla AI's Teleoperation team, focuses on developing low-latency, reliable data streaming solutions for real-world applications.
According to&nbsp;Tesla&#8217;s career page, the company aims to provide remote access to its autonomous vehicles and humanoid robots.
The team is tasked with integrating hardware, firmware, and backend systems to create a sophisticated teleoperation system.
Remote operators will use advanced virtual reality rigs to perform complex tasks, bridging the gap between the physical and digital worlds so remote teleoperators can provide accurate guidance and intervene when necessary.
Engineers will collaborate with hardware teams to define requirements, make design choices, and implement software for the teleoperation system.
Applicants should have experience with C++, Python, 3D graphics, and game engines like Unreal. Familiarity with Windows and Linux environments, networking, and custom shaders is also required.
Tesla's teleoperation role offers a salary range of $120,000 to $318,000, including cash, stock awards, and benefits.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42131163/tesla-ceo-elon-musk-attempts-to-temper-down-expectations-of-30k-optimus-or-cybercab-soon?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab</a>
Why It Matters: The recruitment drive comes at a time when&nbsp;<a href="https://www.benzinga.com/markets/equities/24/11/42029753/teslas-fsd-hits-a-milestone-with-95-mile-unassisted-drive-from-manhattan-to-connecticut-analyst-pierre-ferragu-says-robotaxi-never-felt-that-close-ever-before">Tesla&#8217;s Full Self-Driving (FSD) technology</a>&nbsp;has achieved a significant milestone. Analyst&nbsp;Pierre Ferragu&nbsp;recently highlighted a 95-mile unassisted drive from Manhattan to Connecticut, showcasing Tesla&#8217;s progress in autonomous driving.
Furthermore,&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob">ARK Investment Management</a>&nbsp;has projected that Tesla&#8217;s robotaxi fleet could unlock a staggering $11 trillion revenue potential, surpassing current ride-hailing services like&nbsp;Uber Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and&nbsp;LYFT Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>). This potential revenue stream underscores the importance of Tesla&#8217;s teleoperation capabilities.
Additionally, Tesla&#8217;s&nbsp;<a href="https://www.benzinga.com/news/24/10/41376564/tesla-showcases-optimus-autonomous-navigation-charging-abilities-after-admitting-they-were-human-ass">Optimus robot</a>&nbsp;has demonstrated autonomous navigation and charging abilities, further emphasizing the company&#8217;s advancements in robotics. The robot can now navigate Tesla&#8217;s factory autonomously, avoiding obstacles and interacting with humans.
Price Action: Tesla stock closed 3.80% higher on Friday at $352.56. Year-to-date, it is up 41.92%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42082169/elon-musk-predicts-tesla-cybertrucks-optimus-robots-will-be-aboard-spacex-starships-to-mars-in-2-years?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Predicts Tesla Cybertrucks, Optimus Robots Will Be Aboard SpaceX Starships To Mars In 2 Years</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Tesla

Tech

LYFT

TSLA

UBER

Elon Musk's Tesla Hunts Top Talent To Develop Software For Robotaxi, Optimus Robot Teleoperation

JP Morgan analyst Bryan Smilek initiates coverage on Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) with a Neutral rating and announces Price Target of $8.

COUR

JP Morgan Initiates Coverage On Coursera with Neutral Rating, Announces Price Target of $8

DA Davidson analyst Linda Bolton Weiser upgrades Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from Neutral to Buy and raises the price target from $160 to $209.

DA Davidson Upgrades Procter & Gamble to Buy, Raises Price Target to $209

Canaccord Genuity analyst Edward Nash initiates coverage on Apogee Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) with a Buy rating and announces Price Target of $89.

APGE

Canaccord Genuity Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $89

Wedbush analyst Daniel Ives upgrades Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Outperform and announces $190 price target.

SNOW

Wedbush Upgrades Snowflake to Outperform, Announces $190 Price Target

Jasper gains 11% on data for briquilimab in urticaria

ARS Pharmaceuticals (SPRY) announce seven abstracts will be featured tomorrow, Friday, October 25 at the 2024 ACAAI Annual Scientific Meeting takin...

ARS Pharmaceuticals showcases intranasal epinephrine data at ACAAI meeting

Healthcare Analyst Schimmer, along with Drs. Scarupa and Spergel discuss ARS Pharmaceuticals (SPRY)' Neffy (epinephrine nasal spray), on an Analyst...

Cantor Fitzgerald healthcare analyst holds an analyst/industry conference call

Aquestive: Rare Opportunity With Dual Platform Strategy

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize neffy, ...

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ARS Pharmaceuticals GAAP EPS of -$0.20 misses by $0.05, revenue of $2.07M beats by $1.5M

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript

Ars Pharmaceuticals, Inc. ( ($SPRY) ) has released its Q3 earnings. Here is a breakdown of the information Ars Pharmaceuticals, Inc. presented to i...

ARS Pharmaceuticals' Strong Q3 2024 Highlights

Franklin Biotechnology Discovery Fund Q3 2024 Commentary

ARS Pharmaceuticals: Demand Curve Is Key Unknown

AKBLF

ALLK

ALNY

APLT

AQST

BNTC

CLDX

CNTA

GILD

HLVX

HRTX

JSPR

MRNA

MRUS

NBIX

PCVX

PRAX

PTCT

REGN

RVNC

SLRN

SPRY

VTRS

Press Releases

EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Earnings

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Comments

ARS Pharmaceuticals

ニュース

最新ニュース ARS Pharmaceuticals (NASDAQ:SPRY) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル